Trial Profile

A phase I bridging clinical trial of AL01211

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AL 01211 (Primary)
Indications Fabry's disease
Focus Adverse reactions

Most Recent Events

08 Jan 2025 Results published in the Media Release
17 Aug 2023 New trial record
10 Aug 2023 According to a AceLink Therapeutics media release, the company received IND approval by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com